highli
immunocompromis
pediatr
adult
hematopoiet
cell
transplant
hct
recipi
frequent
experi
respiratori
infect
caus
virus
less
virul
immunocompet
individu
infect
except
rhinoviru
well
adenoviru
parainfluenza
viru
tropic
area
season
variabl
occur
hct
infecti
diseas
manag
includ
sampl
respiratori
specimen
nasopharyng
wash
swab
well
sputum
tracheal
tracheobronchi
lavag
subject
improv
diagnost
tool
includ
multiplex
pcr
assay
routin
use
allow
expedi
detect
respiratori
virus
diseas
progress
along
high
mortal
frequent
associ
respiratori
syncyti
viru
parainfluenza
viru
influenza
viru
metapneumoviru
infect
review
discuss
clinic
find
appropri
use
diagnost
measur
addit
also
discuss
treatment
option
suggest
new
drug
formul
might
prove
use
treat
respiratori
viral
infect
final
shed
light
role
state
immun
reconstitut
use
immunosuppress
drug
outcom
infect
earli
prospect
studi
evalu
incid
respiratori
viral
infect
allogen
hct
recipi
conduct
two
member
european
group
blood
marrow
transplant
ebmt
frequenc
infect
determin
respect
furthermor
highest
mortal
rate
fatal
pneumonia
found
rsv
adv
ljungman
today
year
continu
frequent
infect
still
contribut
signific
mortal
rate
rang
infect
progress
lower
respiratori
tract
boeckh
englund
et
al
renaud
campbel
prothero
et
al
chemali
et
al
spahr
et
al
human
pathogen
virus
frequent
caus
respiratori
infect
allogen
hct
set
includ
rsv
adv
ifv
piv
hmpv
rhv
hcov
hbov
renaud
englund
abba
et
al
respiratori
viru
infect
contribut
morbid
mortal
number
reason
firstli
hct
recipi
suffer
prolong
immunosuppress
lack
humor
cellmedi
immun
impair
viral
clearanc
kohlmeier
woodland
schmidt
varga
addit
patient
usual
antibodydeplet
strength
condit
regimen
ongo
immunosuppress
therapi
diminish
antivir
immun
respons
moreov
type
graft
may
impact
immun
respons
pediatr
hct
recipi
may
also
immunolog
age
secondli
viral
factor
shape
outcom
respiratori
virus
vari
pathogen
ie
caus
sever
diseas
compar
virus
also
capac
certain
strain
given
respiratori
viru
display
increas
virul
case
ifv
therefor
import
identifi
viral
host
gene
determin
virul
thirdli
limit
number
effect
antivir
emerg
drug
resist
also
hamper
success
treatment
final
factor
like
persist
infect
coinfect
comorbid
also
influenc
outcom
contrast
immunocompet
individu
hct
recipi
present
prolong
viral
shed
higher
rate
progress
uri
lri
chemali
et
al
de
lima
et
al
kim
et
al
increas
viral
load
protract
infect
rais
likelihood
progress
differ
virus
uri
commonli
defin
laboratoryconfirm
viral
nasal
wash
swab
pharyng
cough
otiti
nasal
discharg
andor
congest
absenc
infiltr
chest
xray
comput
tomographi
ct
scan
hypoxemia
lri
defin
laboratoryconfirm
viral
nasal
wash
swab
presenc
infiltr
chest
xray
ct
scan
suggest
viral
respiratori
infect
necessarili
detect
viral
nucleic
acid
sampl
obtain
bal
hct
recipi
rsv
frequent
detect
follow
hmpv
piv
case
virus
progress
lri
often
complic
transplant
cours
caus
airflow
obstruct
bronchiol
obliteran
also
increas
rate
mortal
chemali
et
al
sever
respiratori
virus
share
number
risk
factor
associ
lri
occurr
worth
note
cmv
also
repres
opportunist
pathogen
causal
relat
pneumonia
lri
howev
cmv
discuss
review
sinc
primarili
consid
respiratori
viru
said
cmv
pathogen
frequent
occur
part
simultan
infect
inde
respiratori
viral
infect
often
preced
bacteri
fungal
infect
thu
complic
associ
respiratori
viru
infect
need
acknowledg
review
focu
respiratori
viru
infect
particularli
commonli
detect
hct
highlight
risk
factor
facilit
progress
uri
lri
discuss
diagnost
approach
current
treatment
strategi
along
new
treatment
option
discuss
adenoviru
member
adenovirida
circul
throughout
year
current
human
type
known
divid
seven
speci
ag
access
august
alongsid
conjunct
diarrhea
adv
caus
pharyng
bronchiti
pneumonia
also
lethal
hepat
sever
bloodi
coliti
pertin
review
adv
pathogen
associ
sever
complic
immunosuppress
pediatr
hct
recipi
includ
increas
mortal
leen
et
al
feuchting
et
al
lion
feucht
et
al
hiwarkar
et
al
adult
patient
adv
infect
less
commonli
report
howev
possibl
percept
might
bias
reduc
frequenc
screen
adult
studi
adult
allogen
hct
recipi
report
infect
rate
pneumonia
occur
case
common
caus
death
associ
adv
yilmaz
et
al
import
consider
adv
infect
infrequ
present
respiratori
symptom
onset
infect
instead
commonli
detect
monitor
stool
lo
et
al
lion
inde
gastrointestin
shed
pretranspl
demonstr
reflect
increas
risk
viremia
hct
kosulin
et
al
human
bocaviru
identifi
human
pathogen
caus
respiratori
tract
infect
infant
assign
parvovirida
receiv
name
sequenc
homolog
two
member
genu
bocaparvoviru
bovin
parvoviru
infect
cattl
canin
minut
viru
infect
dog
alland
et
al
current
four
hbov
variant
describ
like
enter
episom
state
allow
establish
persist
infect
kapoor
et
al
wherea
caus
gastroenter
genet
divers
exhibit
stronger
associ
lri
enter
often
conjunct
respiratori
pathogen
limit
genet
divers
although
reinfect
differ
variant
occur
arden
et
al
ditt
et
al
arthur
et
al
kapoor
et
al
wang
et
al
martin
et
al
symptom
follow
infect
includ
cough
dyspnea
pharyng
bronchiti
pneumonia
diarrhea
sever
report
suggest
caus
sever
infect
mere
bystand
viru
ursic
et
al
edner
et
al
likewis
hbov
caus
lifethreaten
infect
prolong
shed
immunocompromis
patient
immunocompet
children
median
shed
time
day
report
kupfer
et
al
alland
koskenvuo
et
al
de
vri
et
al
martin
et
al
long
shed
period
might
lead
sever
diseas
immunocompromis
children
schenk
et
al
importantli
hbov
exhibit
season
thu
remain
threat
throughout
year
human
coronaviru
belong
coronavirida
endem
human
annual
hcov
respons
uri
pharyng
rhiniti
immunocompet
host
histor
two
common
hcov
known
howev
emerg
sever
acut
respiratori
syndromecoronaviru
sarscov
along
two
hcov
expand
famili
van
der
hoek
et
al
woo
et
al
contrast
low
incid
bronchiti
pneumonia
healthi
children
sever
clinic
featur
describ
immunocompromis
patient
presenc
respiratori
copathogen
rsv
host
factor
like
young
age
year
immunocompromis
statu
report
contribut
lri
howev
note
children
hct
includ
ogimi
et
al
ogimi
et
al
separ
studi
hcov
associ
increas
mortal
prolong
shed
hct
set
milano
et
al
renaud
campbel
risk
factor
prolong
shed
least
day
upper
respiratori
tract
determin
cohort
patient
includ
high
viral
load
myeloabl
condit
prior
highdos
steroid
use
ogimi
et
al
patient
sampl
analyz
shown
contain
evid
infect
analysi
durat
shed
show
none
strain
appear
caus
longer
shed
compar
other
addit
genom
approach
investig
whether
viral
genom
evolut
could
identifi
genet
chang
associ
prolong
shed
identif
chang
could
aid
develop
new
antivir
agent
singl
nucleotid
polymorph
could
identifi
day
thirti
onset
viral
shed
find
might
surpris
given
protract
evolut
rate
hcov
howev
overt
viral
genom
chang
might
occur
later
time
point
chang
genom
composit
might
result
modif
treatment
strategi
ogimi
et
al
anoth
studi
hcov
examin
bal
ogimi
et
al
median
time
hcov
lri
occurr
day
hct
among
bal
sampl
analyz
detect
although
somewhat
limit
sampl
size
data
show
similar
frequenc
order
detect
viral
strain
compar
detect
nasal
sampl
except
predomin
nasal
sampl
ogimi
et
al
detect
rsv
chang
clinic
outcom
influenza
viru
orthomyxovirida
member
exhibit
high
genom
variabl
due
absenc
proofread
activ
rna
process
contribut
antigen
drift
ifv
strain
virul
other
strain
ifv
impact
sever
depend
circul
strain
impact
upon
composit
vaccin
also
uptak
vaccin
popul
individu
compromis
immun
system
elderli
hct
recipi
increas
risk
complic
death
outbreak
hct
unit
report
lalayanni
et
al
suyani
et
al
hct
recipi
fever
mayb
absent
case
might
classic
symptom
sore
throat
nasal
congest
discharg
cough
chill
myalgia
respiratori
virus
ifv
shed
hct
patient
report
prolong
median
day
lymphopenia
correl
durat
shed
steroid
use
mgkg
increas
ifv
secret
khanna
et
al
boudreault
et
al
engelhard
et
al
infant
may
present
sepsislik
symptom
pneumonia
complic
adult
includ
pneumonia
myocard
enceph
syndrom
piv
infect
see
bacteri
fungal
coinfect
ifv
known
nichol
et
al
engelhard
et
al
diseas
progress
lri
take
place
mortal
rang
patient
diagnos
pneumonia
therefor
earli
treatment
within
day
present
symptom
favor
whimbey
et
al
nichol
et
al
chemali
et
al
kmeid
et
al
risk
factor
valid
rsv
piv
equival
qualiti
indic
limit
ifv
potenti
risk
factor
might
result
lri
lymphopenia
neutropenia
well
increas
age
year
steroid
use
unclear
ljungman
et
al
chemali
et
al
choi
et
al
ifv
genom
detect
blood
associ
hypoxemia
respiratori
failur
overal
mortal
choi
et
al
kmeid
et
al
appli
isi
develop
rsv
identifi
patient
ifv
infect
might
run
risk
develop
progress
lri
accord
variabl
age
neutrophil
lymphocyt
count
condit
regimen
steroid
use
time
transplant
hct
recipi
group
low
moder
high
risk
immunodefici
categori
high
risk
score
appli
score
like
includ
anc
score
andor
alc
age
year
myeloabl
regimen
gvhd
steroid
use
within
last
day
recent
within
last
day
preengraft
allogen
hct
patient
high
risk
score
significantli
higher
probabl
develop
lri
compar
low
risk
group
kmeid
et
al
human
metapneumoviru
formerli
member
paramyxovirida
belong
pneumovirida
identifi
agent
capabl
caus
respiratori
diseas
children
van
den
hoogen
et
al
immunocompet
individu
hmpv
caus
symptomat
uri
lri
predominantli
children
adult
year
age
boivin
et
al
specif
symptom
distinguish
hmpv
viral
respiratori
infect
exist
report
diseas
sever
case
rsv
coinfect
data
consid
controversi
immunocompet
children
one
studi
reveal
hmpv
rsv
coinfect
increas
bronchiol
sempl
et
al
howev
could
substanti
studi
investig
singl
infect
coinfect
hmpv
rsv
moe
et
al
yan
et
al
hmpv
rsv
b
type
occur
distinguish
differ
primer
set
pcr
renaud
et
al
immunocompromis
children
higher
risk
develop
lri
higher
risk
requir
intens
care
treatment
increas
mortal
chu
et
al
studi
hct
recipi
hpmv
infect
document
major
patient
caus
symptom
diseas
debiaggi
et
al
howev
studi
includ
episod
uri
lri
episod
hpmv
detect
occur
hct
recipi
result
infect
rate
approxim
hct
patient
anoth
studi
reveal
hpmv
bal
sampl
patient
becam
symptomat
within
month
engraft
fatal
reach
bal
posit
hmpv
englund
et
al
progress
lri
report
take
place
renaud
campbel
hmpv
risk
factor
mortal
includ
length
hct
infect
neutropenia
lymphopenia
low
monocyt
count
diagnosi
steroid
dose
diagnosi
mgkg
seo
et
al
latter
studi
presenc
copathogen
contribut
higher
risk
glucocorticoid
applic
lymphopenia
identifi
risk
factor
contribut
progress
uri
lri
seo
et
al
systemat
review
hmpv
progress
lri
case
mortal
rate
increas
lri
present
hmpvassoci
risk
factor
increas
mortal
could
identifi
shah
et
al
parainfluenza
viru
member
paramyxovirida
circul
throughout
year
piv
caus
lri
approxim
healthi
children
bicer
et
al
also
respons
lifethreaten
lri
hct
recipi
srinivasan
et
al
shah
et
al
four
piv
serotyp
known
piv
serotyp
frequent
occur
serotyp
respons
infect
hct
cortez
et
al
nichol
et
al
maziarz
et
al
hodson
et
al
one
studi
compris
patient
piv
infect
infect
patient
develop
pneumonia
nichol
et
al
anoth
studi
report
piv
infect
case
first
month
post
hct
patient
experi
uri
infect
progress
lri
median
time
day
virusassoci
mortal
around
piv
infect
increas
infect
progress
lri
nichol
et
al
srinivasan
et
al
chemali
et
al
ustun
et
al
seo
et
al
shah
et
al
piv
risk
factor
progress
lri
lymphopenia
steroid
use
coinfect
respiratori
agent
howev
myeloabl
infect
earli
posttranspl
period
variabl
unclear
associ
seo
et
al
shah
et
al
pulmonari
copathogen
eg
aspergillu
fumigatu
often
present
patient
pneumonia
highli
contribut
mortal
nichol
et
al
ustun
et
al
respiratori
syncyti
viru
also
belong
pneumovirida
frequent
pathogen
infant
children
caus
uri
rhiniti
laryng
also
bronchiti
pneumonia
progress
lri
occur
hct
recipi
rsv
infect
occur
khanna
et
al
avetisyan
et
al
shah
chemali
waghmar
et
al
approxim
half
hct
recipi
uri
caus
rsv
infect
progress
result
pneumonia
associ
averag
mortal
rate
around
without
effect
treatment
nichol
et
al
boeckh
et
al
khanna
et
al
shah
chemali
seo
et
al
waghmar
et
al
risk
factor
progress
lri
includ
advanc
age
lymphopenia
myeloabl
regimen
steroid
use
gvhd
preengraft
infect
occur
mean
nichol
et
al
martino
et
al
khanna
et
al
shah
chemali
hirsch
et
al
smoke
histori
condit
highdos
total
bodi
irradi
cgi
specif
absolut
lymphocyt
count
uri
onset
significantli
associ
progress
lri
contrast
lung
function
steroid
use
lymphocyt
engraft
dynam
rsv
subtyp
subtypespecif
neutral
antibodi
level
associ
progress
reveal
transplantrel
rather
viral
factor
might
put
focu
character
rsvspecif
cell
kim
et
al
addit
absolut
lymphocyt
count
uri
onset
protect
advanc
lri
observ
anoth
studi
examin
risk
factor
rsv
rna
detect
serum
plasma
identifi
mechan
ventil
neutropenia
monocytopenia
well
thrombocytopenia
associ
factor
howev
lymphopenia
steroid
use
increas
risk
rsv
rna
plasma
detect
waghmar
et
al
studi
median
time
day
lri
onset
describ
describ
ifv
isi
origin
propos
stratifi
rsvinfect
patient
group
base
risk
progress
uri
lri
evalu
rsvrelat
mortal
stratif
help
identifi
patient
might
profit
antivir
therapi
aerosol
ribavirin
index
base
age
absolut
neutrophil
lymphocyt
count
acut
chronic
gvhd
myeloabl
condit
corticosteroid
use
time
infect
howev
valid
index
need
perform
multicent
studi
rhinoviru
member
picornavirida
compris
serotyp
divid
three
speci
b
c
season
prefer
rhv
howev
infect
might
occur
spring
autumn
rhv
frequent
detect
communityassoci
respiratori
virus
caus
cough
runni
nose
also
bronchiti
pneumonia
hct
recipi
ison
et
al
milano
et
al
symptomat
rhv
infect
occur
hct
recipi
initi
high
viral
load
associ
prolong
shed
parodi
et
al
milano
et
al
ogimi
et
al
recent
studi
show
median
shed
time
among
patient
rhv
infect
day
hct
recipi
prolong
rhv
shed
least
day
rang
day
similar
three
speci
major
patient
shed
rhv
speci
risk
factor
prolong
rhv
shed
point
high
initi
viral
load
defin
ct
valu
median
ogimi
et
al
infect
control
measur
consid
long
infect
period
progress
lri
increasingli
detect
fatal
outcom
due
rhv
infect
describ
gutman
et
al
jacob
et
al
ogimi
et
al
patient
reveal
respiratori
tract
infect
symptom
hct
test
respiratori
pathogen
multiplex
pcr
campbel
et
al
analyz
data
adult
pediatr
patient
identifi
patient
posit
least
one
respiratori
viru
pretranspl
symptomat
patient
lower
surviv
day
hct
compar
patient
neg
test
result
increas
overal
mortal
sinc
risk
increas
even
rhv
detect
author
propos
consid
deferr
hct
symptomat
patient
respiratori
viru
posit
case
rsv
ifv
piv
hmpv
detect
asymptomat
patient
viru
detect
exhibit
higher
mortal
hct
might
proceed
plan
howev
unclear
patient
actual
shed
replic
viru
viral
nucleic
acid
detect
higher
incid
bronchoscopi
symptomat
versu
asymptomat
group
decis
delay
transplant
consid
hct
factor
underli
diseas
condit
regimen
associ
donor
logist
campbel
et
al
followup
studi
focus
pediatr
hct
recipi
kim
et
al
detect
respiratori
virus
pretranspl
patient
rhv
detect
case
follow
group
virus
consist
adv
rsv
hmpv
pfv
piv
pretranspl
detect
associ
increas
hospit
first
day
hcov
detect
pretranspl
case
sinc
condit
regimen
might
impact
incid
respiratori
viru
infect
pretranspl
patient
myeloabl
nonmyeloabl
condit
compar
incid
respiratori
viru
infect
similar
among
group
howev
contrast
patient
receiv
nonmyeloabl
condit
lri
significantli
increas
first
day
post
hct
myeloabl
regimen
given
schiffer
et
al
immedi
hct
neutropen
phase
patient
frequent
develop
febril
episod
especi
prone
bacteri
infect
therefor
often
treat
antibiot
protect
lifethreaten
bacteri
infect
treatment
alter
microbiota
composit
impact
immun
respons
ichinoh
et
al
abt
et
al
dyer
et
al
immunodulatori
compound
associ
microbiota
butyr
short
chain
fatti
acid
import
maintain
gut
microbiom
equilibrium
well
control
immun
respons
organ
lung
donoho
et
al
chang
et
al
recent
studi
haak
et
al
investig
influenc
butyr
microbiota
composit
influenc
respiratori
viral
infect
associ
risk
develop
lri
hct
recipi
patient
receiv
antibiot
treatment
result
alter
microbiota
colon
diminish
butyrateproduc
bacteria
higher
risk
develop
lri
indic
presenc
butyrateproduc
bacteria
appear
protect
haak
et
al
recent
analysi
seattl
group
shown
antibiot
exposur
onset
viral
respiratori
infect
increas
risk
progress
uri
lri
case
hmpv
piv
rsv
infect
ogimi
et
al
howev
certain
class
antibiot
pose
particular
risk
could
identifi
anoth
recent
studi
describ
signific
lower
overal
surviv
patient
respiratori
viru
infect
accompani
bacteri
coinfect
contribut
increas
mortal
pinana
et
al
risk
factor
develop
bacteri
coinfect
follow
respiratori
viral
infect
steroid
use
cmv
dnaemia
requir
antivir
therapi
mortalityassoci
risk
factor
lymphopenia
cmv
dnaemia
requir
antivir
therapi
time
viral
lri
diagnosi
oxygen
support
time
bal
use
establish
risk
score
order
stratifi
patient
help
predict
mortal
matter
coinfect
present
new
risk
score
compar
score
includ
isi
describ
howev
applic
isi
criteria
prove
use
predict
mortal
cohort
current
isi
includ
coinfect
variabl
futur
studi
need
valid
compar
differ
risk
score
pinana
et
al
profound
lymphopenia
hct
describ
risk
factor
studi
multipl
studi
recent
suggest
cell
may
protect
secondari
infect
schmidt
varga
fourth
european
confer
infect
leukemia
develop
guidelin
diagnosi
treatment
sever
respiratori
virus
hirsch
et
al
hct
candid
recipi
uri
lri
test
respiratori
virus
guid
infect
manag
possibl
deferr
transplant
specimen
taken
site
infect
uri
pool
swab
analyz
lri
tracheal
aspir
ideal
bal
perform
howev
patient
circumst
often
permit
invas
procedur
guidelin
favor
firstlin
screen
ifv
b
rsv
piv
howev
advanc
multiplex
pcr
assay
becom
avail
agent
might
examin
waghmar
et
al
past
year
respiratori
infect
hct
recipi
report
due
develop
use
new
diagnost
method
routin
molecular
diagnost
respiratori
virus
nowaday
includ
multiplex
pcr
approach
improv
detect
respiratori
agent
hct
recipi
leber
et
al
sam
et
al
multiplex
assay
cover
relev
respiratori
viral
agent
prefer
labori
timeconsum
viral
cultur
direct
fluoresc
antibodi
assay
sensit
specif
rapid
turnaround
time
addit
viral
nucleic
acid
quantif
import
determin
viral
load
might
indic
prolong
viral
shed
case
rhv
ogimi
et
al
howev
provid
inform
activ
replic
viral
cultur
techniqu
well
establish
eg
hcov
problem
viru
detect
lack
standard
among
assay
sinc
differ
primer
probe
techniqu
use
huang
et
al
nasal
respiratori
swab
routin
perform
pretranspl
collect
case
suspect
respiratori
infect
larg
prospect
studi
associ
respiratori
viru
detect
transplant
prolong
hospit
decreas
surviv
day
campbel
et
al
rhv
detect
routin
pretranspl
screen
result
fatal
infect
even
patient
asymptomat
present
regular
find
chest
ct
milano
et
al
campbel
et
al
waghmar
et
al
respiratori
viru
identifi
multiplex
pcr
pretranspl
hct
postpon
peck
et
al
hirsch
et
al
howev
occur
leukemia
relaps
case
time
window
remiss
hct
narrow
thu
make
decis
difficult
irrespect
uri
lri
transplant
delay
possibl
probabl
even
case
data
scarc
case
hcov
hbov
infect
episod
uri
lri
shown
higher
mortal
risk
symptomat
adult
contrast
asymptomat
patient
abandeh
et
al
transplant
delay
recommend
symptomat
adult
howev
pediatr
patient
tend
shed
viru
frequent
adult
acquir
virus
frequent
transplant
delay
consid
case
case
basi
asymptomat
patient
aid
determin
progress
uri
lri
radiolog
sign
consid
import
compon
although
interobserv
variabl
high
radiolog
sign
sometim
difficult
interpret
elemraid
et
al
franquet
import
perform
use
radiolog
diagnost
symptomat
patient
suspect
lri
chest
xray
gener
recommend
lack
sensit
ct
perform
evalu
lri
children
chest
xray
provid
specif
inform
case
hmpv
infect
common
find
includ
hyperinfl
atelectasi
perihilar
opac
hilm
et
al
attempt
tri
provid
standard
framework
score
tool
name
rsi
establish
quantifi
sever
radiolog
find
correl
outcom
piv
lri
infiltr
expans
longitudin
assess
rsi
predict
mortal
patient
pivassoci
diseas
discrep
result
obtain
ct
chest
xray
find
compar
earli
sign
suggest
rsi
appear
use
tool
predict
mortal
need
valid
futur
studi
sheshadri
et
al
comput
tomographi
find
associ
lri
includ
bronchial
wall
thicken
diffus
patchlik
ground
glass
opac
sign
interstiti
infiltr
franquet
et
al
herbst
et
al
howev
radiolog
approach
often
show
clear
sign
infect
symptomat
patient
addit
occurr
simultan
infect
mean
correl
specif
viru
ct
find
difficult
address
retrospect
studi
kim
et
al
examin
ct
scan
lri
patient
bal
specimen
singl
infect
either
rsv
ifv
piv
order
identifi
viruscharacterist
ct
lesion
patch
consolid
least
one
centimet
one
segment
level
observ
piv
infect
groundglass
opac
identifi
ct
scan
ifv
detect
less
frequent
seen
piv
detect
case
rsv
bronchial
wall
thicken
promin
ifv
rsv
two
third
ct
scan
analyz
wherea
seen
one
third
piv
infect
anatom
rsv
infect
local
upper
middl
lobe
piv
preferenti
lower
lobe
ifv
infect
result
diffus
pattern
kim
et
al
howev
due
retrospect
natur
studi
kim
et
al
distinct
earli
late
infect
stage
ct
find
could
made
might
reveal
differ
pattern
studi
similarli
identifi
groundglass
opac
ifv
infect
franquet
et
al
kann
et
al
bronchial
wall
thicken
combin
nodul
treeinbud
rsv
infect
mayer
et
al
anoth
small
studi
also
detect
bronchial
wall
thicken
patient
confirm
rsv
infect
also
groundglass
opac
find
equal
seen
hmpv
infect
lesion
appear
asymmetr
syha
et
al
although
ct
find
appear
nonspecif
might
help
differenti
pathogen
caus
lri
thorough
diagnost
workup
includ
multiplex
pcr
repres
specimen
employ
larg
rule
simultan
infect
infect
control
measur
high
import
place
case
suspect
confirm
respiratori
viru
infect
boeckh
sinc
virus
transmit
close
contact
infect
individu
contamin
materi
hand
hygien
utmost
import
sinc
nosocomi
infect
occur
must
avoid
hoellein
et
al
use
univers
surgic
mask
might
also
use
prevent
respiratori
viral
infect
hct
sung
et
al
patient
document
respiratori
viru
infect
isol
restrict
contact
strict
protect
measur
appli
glove
gown
mask
eye
protect
visitor
healthcar
worker
hirsch
et
al
sinc
hct
recipi
might
shed
virus
long
time
impair
immun
precaut
taken
patient
discharg
exampl
patient
escort
outpati
clinic
avoid
direct
contact
spread
patient
prolong
isol
might
necessari
tomblyn
et
al
hirsch
et
al
might
especi
import
rhv
case
high
viral
load
detect
sinc
shed
time
patient
exce
day
ogimi
et
al
howev
hmpv
infect
might
go
unrecogn
immunocompet
person
thu
make
difficult
prevent
infect
nichol
et
al
debiaggi
et
al
shah
et
al
birger
et
al
time
respiratori
tract
infect
proven
hct
reduct
immunosuppress
treatment
respons
steroid
dose
greater
mgkgday
proven
independ
risk
factor
overal
mortal
lri
rhv
seo
et
al
rsv
shah
et
al
hmpv
piv
waghmar
et
al
howev
correl
progress
mortal
steroid
dose
found
ifv
waghmar
et
al
adenoviru
pneumonia
usual
observ
adv
dissemin
diseas
preemptiv
treatment
recommend
soon
viremia
higher
equal
copiesml
coupl
lymphocyt
count
lymphocyt
count
hiwarkar
et
al
particularli
import
high
risk
patient
receiv
cord
blood
graft
steroid
treatment
lindeman
et
al
high
adv
level
stool
also
associ
gastrointestin
adv
diseas
feghoul
et
al
observ
underpin
current
clinic
trial
address
use
preemptiv
treatment
base
stool
adv
detect
far
recommend
made
adv
detect
upper
airway
specif
treatment
adv
pneumonia
given
earli
possibl
diagnosi
neofyto
et
al
lindeman
et
al
sever
studi
report
success
cidofovir
treatment
adv
infect
immunocompromis
host
hct
combin
withdraw
immunosuppress
eg
mgkg
everi
week
week
follow
mainten
dose
mgkg
everi
fortnight
three
time
weekli
mgkg
lindeman
et
al
wy
ip
qasim
cidofovir
inhibit
incorpor
deoxycytidin
triphosph
http
viral
dna
viral
dna
polymeras
lead
viral
dna
chain
termin
probenecid
coprescript
use
prevent
diminish
cidofovir
nephrotox
due
accumul
renal
tubul
cidofovir
current
standard
care
treatment
adv
infect
diseas
howev
cidofovir
clear
viru
absenc
cell
immun
reconstitut
hiwarkar
et
al
anoth
novel
compound
hexadecyloxypropyl
cidofovir
brincidofovir
chimerix
oral
bioavail
lipid
conjug
cidofovir
good
oral
bioavail
achiev
higher
intracellular
level
activ
drug
compar
cidofovir
brincidofovir
lack
nephrotox
make
attract
altern
phase
phase
ii
trial
well
retrospect
studi
brincidofovir
shown
highli
efficaci
control
clear
adenoviraemia
grimley
et
al
hiwarkar
et
al
ramsay
et
al
averbuch
et
al
gastrointestin
toxic
major
side
effect
observ
might
associ
epitheli
apoptosi
crypt
injuri
might
observ
gvhd
detweil
et
al
small
compound
inhibitor
name
hbx
report
effect
adv
infect
cellular
compon
import
adv
replic
ubiquitinspecif
proteas
deubiquitin
enzym
ubiquitin
proteasom
pathway
interact
regul
adv
replic
sinc
promot
adv
replic
repres
potenti
drug
target
block
activ
could
aid
treatment
adv
infect
ching
et
al
hbx
deriv
gener
abl
block
adv
type
replic
except
adv
type
hbx
effect
block
vitro
replic
adv
test
make
promis
new
antivir
candid
kosulin
et
al
adv
proven
role
ganciclovir
foscarnet
immunoglobulin
therapi
immunocompromis
patient
importantli
donor
lymphocyt
infus
recent
specif
anti
adv
cytototox
cell
consid
case
adv
diseas
hct
see
anecdot
evid
success
treatment
adv
ribavirin
schleun
et
al
studi
support
lankest
et
al
conclud
cidofovir
combin
immunotherapi
effici
prefer
first
treatment
option
note
ribavirin
activ
vitro
speci
c
isol
morfin
et
al
current
recommend
specif
antivir
therapi
due
lack
effect
agent
virus
lack
clinic
trial
hirsch
et
al
sever
agent
rhv
describ
context
immunosuppress
oral
intranas
pleconaril
capsid
binder
effect
random
trial
mildli
reduc
durat
sever
cold
immunocompet
adult
develop
halt
fda
reject
partli
due
concern
regard
viru
resist
senior
vapendavir
anoth
capsid
binder
develop
treatment
rhv
infect
asthmat
adult
waghmar
et
al
avoid
transmiss
ifv
vaccin
famili
member
household
contact
hct
recipi
recommend
howev
hct
recipi
might
mount
adequ
immun
respons
vaccin
take
place
immunosuppress
avail
antivir
ifv
infect
includ
ion
channel
inhibitor
amantadin
exclus
act
ifva
howev
neuraminidas
inhibitor
nai
prefer
prophylaxi
treatment
ifv
infect
sinc
resist
inhibitor
frequent
englund
et
al
fior
et
al
von
lilienfeldto
et
al
post
exposur
prophylaxi
oral
oseltamivir
mg
bid
day
adult
children
whose
weight
kg
current
treatment
choic
oral
oseltamivir
inhal
zanamivir
iv
peramivir
nai
shown
effect
hct
recipi
vu
et
al
tomblyn
et
al
casper
et
al
choi
et
al
engelhard
et
al
treatment
within
h
occurr
symptom
result
better
outcom
ljungman
et
al
nichol
et
al
tomblyn
et
al
choi
et
al
engelhard
et
al
although
treatment
initi
earli
possibl
protract
also
prolong
treatment
shown
favor
effect
durat
therapi
extend
treatment
period
recommend
immunocompet
host
circumv
reoccurr
might
last
day
hct
recipi
also
longer
therapi
case
unsuccess
clearanc
might
necessari
engelhard
et
al
commonli
describ
mutat
result
oseltamivir
peramivir
resist
confer
mutat
influenza
treat
inhal
zanamivir
memoli
et
al
engelhard
et
al
europ
winter
season
high
resist
rate
ifva
oseltamivir
report
meijer
et
al
new
agent
potenti
efficaci
oseltamivirresist
virus
test
like
inhal
laninamivir
avail
japan
nonnucleosid
inhibitor
rna
polymeras
protein
nitazoxanid
antiparasit
agent
activ
ifv
antibodi
shahani
et
al
retrospect
analysi
patient
includ
hct
recipi
onethird
patient
piv
infect
lower
respiratori
tract
diseas
independ
risk
factor
progress
neutropenia
apach
ii
score
respiratori
coinfect
within
month
piv
infect
studi
treatment
aerosol
ribavirin
andor
ivig
prevent
progress
pneumonia
affect
durat
ill
surviv
chemali
et
al
metaanalysi
perform
reinforc
evid
ineffici
ribavirin
piv
inde
pilri
progress
significantli
http
differ
hct
recipi
treat
ribavirin
uri
stage
pivassoci
mortal
rate
slightli
higher
patient
treat
ribavirinbas
therapi
lri
stage
treat
shah
et
al
recombin
sialidas
fusion
protein
inhibitor
name
use
treat
sever
piv
infect
hct
waghmar
et
al
dhakal
et
al
salvator
et
al
cleav
gal
gal
sialic
acid
linkag
surfac
respiratori
cell
use
ifv
piv
attach
entri
therebi
inhibit
latter
largest
cohort
includ
patient
hct
receiv
pivassoci
pneumonia
unfortun
lack
control
group
salvator
et
al
thirteen
patient
respond
treatment
three
patient
respond
viral
bacteri
fungal
coinfect
respect
drug
well
toler
piv
load
record
patient
use
nasopharyng
swab
log
decreas
piv
load
seen
patient
accompani
partial
complet
clinic
respons
highdos
ivig
effect
mortal
piv
lri
retrospect
analysi
patient
piv
infect
hct
seo
et
al
therefor
specif
treatment
piv
infect
current
strongli
recommend
howev
current
guidelin
suggest
treatment
aerosol
ribavirin
offlabel
use
system
ribavirin
infect
piv
rsv
ribavirin
use
recommend
hirsch
et
al
studi
among
patient
uri
fred
hutchinson
cancer
center
seo
et
al
probabl
progress
lri
within
day
approxim
patient
uri
progress
lri
within
week
uri
even
sever
small
report
support
use
ribavirin
without
ivig
hmpv
infect
larger
studi
show
protect
effect
ribavirin
reduc
hmpv
progress
mortal
renaud
et
al
date
antivir
therapi
recommend
cure
prevent
infect
progress
even
patient
higher
risk
hmpv
progress
licens
therapeut
vaccin
exist
wen
william
therefor
treatment
hmpv
remain
far
nonspecif
mainli
support
mab
monoclon
antibodi
fusion
protein
hmpv
demonstr
interest
result
hamster
mice
model
investig
clinic
trial
warrant
ulbrandt
et
al
hamelin
et
al
intern
guidelin
recommend
aerosol
system
oral
iv
ribavirin
ivig
patient
rsv
uri
undergo
allogen
hct
allogen
hct
recipi
risk
factor
progress
lri
allogen
hct
patient
lri
hirsch
et
al
howev
addit
benefit
ivig
remain
controversi
retrospect
studi
review
rsv
uri
lri
infect
hct
recipi
combin
ivig
ribavirin
treatment
benefici
shah
et
al
given
signific
exponenti
cost
increas
aerosol
ribavirin
lack
evid
aerosol
ribavirin
effici
earli
oral
ribavirin
treatment
current
frequent
consid
waghmar
et
al
well
toler
eg
mgkgday
three
divid
dose
day
gorcea
et
al
clinic
trial
compar
rsv
treatment
oral
versu
inhal
ribavirin
ongo
howev
franc
aerosol
ribavirin
current
avail
lymphopenia
specif
risk
factor
associ
progress
lrti
sever
studi
risk
factor
total
bodi
irradi
smoke
histori
stem
cell
sourc
peripher
blood
stem
cell
oxygen
requir
might
consid
waghmar
et
al
lower
virul
rsvb
compar
rsva
report
kelli
et
al
state
isi
might
help
identifi
patient
would
benefit
antivir
therapi
shah
et
al
data
studi
rsvspecif
monoclon
antibodi
palivizumab
shown
controversi
efficaci
apart
fact
costli
adult
larger
studi
hct
recipi
rsv
lri
adjunct
palivizumab
lead
outcom
improv
waghmar
et
al
therefor
rsvspecif
monoclon
antibodi
recommend
treatment
option
might
discuss
http
young
age
year
allogen
hct
recipi
lri
high
risk
progress
rsv
lri
eg
palivizumab
mgkg
bodi
weight
hirsch
et
al
moreov
sever
agent
develop
rsv
infect
shahani
et
al
firstli
fusion
inhibitor
like
reduc
viral
load
sever
clinic
diseas
studi
healthi
adult
devincenzo
et
al
secondli
agent
target
rsv
polymeras
exist
interest
antivir
activ
compar
placebo
healthi
adult
inocul
rsv
devincenzo
et
al
favipiravir
current
test
phase
iii
clinic
trial
unit
state
europ
latin
america
thirdli
substanc
target
viral
nucleocapsid
protein
investig
small
interf
rna
call
aln
inhibit
synthesi
rsv
nucleocapsid
protein
demonstr
benefit
phase
iib
clinic
trial
decreas
infect
rate
reduc
symptom
incid
bronchiol
obliteran
anoth
drug
target
n
termin
portion
nucleocapsid
protein
test
hct
recipi
howev
data
publish
et
al
final
polyclon
hightit
anti
rsv
antibodi
might
option
current
strategi
recommend
treatment
respiratori
viral
diseas
hct
molecul
investig
summar
tabl
era
specif
antivir
manufactur
cell
donor
lymphocyt
infus
dli
use
recommend
case
dissemin
adv
infect
hct
bordigoni
et
al
taniguchi
et
al
high
incid
gvhd
dli
limit
use
patient
previou
histori
gvhd
anecdot
use
dli
report
threaten
rsv
lri
kishi
et
al
current
three
strategi
manufactur
viral
specif
cell
vst
clinic
use
first
one
direct
select
antivir
cell
either
multim
specif
virusderiv
peptid
set
class
hla
molecul
column
select
express
cell
immunomagnet
bead
viral
antigen
stimul
feuchting
et
al
pegg
et
al
icheva
et
al
second
one
ex
vivo
expans
cell
cocultur
antigen
present
cell
puls
infect
transfect
viral
peptideproteinvir
lysat
plasmid
pegg
et
al
gerdemann
et
al
gerdemann
et
al
third
one
genet
modif
cell
incorpor
high
affin
vst
receptor
chimer
antigen
receptor
gene
schub
et
al
cruz
et
al
bollard
heslop
far
set
commun
acquir
viral
respiratori
infect
adopt
immun
therapi
develop
investig
clinic
trial
adv
infect
strategi
promis
report
offer
way
cure
sever
adenovir
infect
case
resist
antivir
drug
adenovir
clearanc
obtain
infus
advvst
gener
interferon
immunomagnet
isol
vivo
expans
initi
donor
third
parti
donor
hematopoiet
stem
cell
transplant
patient
french
phase
iii
trial
qian
et
al
similar
result
publish
earlier
feucht
et
al
patient
receiv
advvst
adv
diseas
viremia
evalu
patient
vivo
expans
median
time
day
patient
respond
vst
infus
adv
clearanc
occur
note
advvst
infus
associ
acut
toxic
signific
onset
gvhd
main
disadvantag
techniqu
high
dose
immunosuppress
drug
especi
steroid
avoid
infus
drug
hamper
vivo
expans
specif
cell
current
multivir
includ
adv
cell
manufactur
bank
thirdparti
donor
promis
strategi
might
offer
immedi
way
prevent
adv
infect
hct
cure
adv
infect
patient
hct
ex
vivo
expand
cytotox
cell
antigen
test
clinic
trial
mclaughlin
et
al
aguayohiraldo
et
al
outcom
patient
experi
progress
lri
wors
compar
patient
uri
regardless
viru
involv
chemali
et
al
french
cohort
adult
patient
infect
viral
respiratori
infect
die
within
month
among
eight
patient
die
viral
pneumonia
along
bacteri
andor
fungal
pneumonia
interestingli
viru
group
time
hct
impact
mortal
two
factor
independ
associ
increas
overal
mortal
steroid
dose
mgkg
bodi
weight
lymphocyt
count
lower
gl
wolfromm
et
al
fact
lri
associ
death
risk
depend
viru
type
support
seo
et
al
report
overal
mortal
probabl
day
high
patient
hct
develop
rhv
lri
rate
compar
rsv
piv
ifv
lri
adjust
model
among
children
cohort
patient
die
respiratori
failur
choi
et
al
lri
absenc
uri
adenovir
infect
describ
associ
poorer
outcom
anoth
cohort
patient
specif
overal
mortal
lo
et
al
bronchiol
obliteran
syndrom
obstruct
airflow
declin
associ
piv
rsv
infect
within
first
month
allogen
hct
persist
year
transplant
versluy
et
al
occurr
lri
within
day
posttranspl
independ
predict
factor
late
onset
noninfecti
pulmonari
complic
diagnos
first
month
transplant
observ
prospect
cohort
studi
patient
bergeron
et
al
therefor
function
pulmonari
explor
longterm
surveil
warrant
commun
acquir
viral
infect
occur
earli
hct
better
understand
risk
factor
pulmonari
complic
children
hct
multicentr
french
trial
ongo
earli
treatment
mimet
inhal
steroid
might
use
propos
case
persist
obstruct
syndrom
respiratori
viral
infect
resolut
hct
recipi
review
limit
present
result
small
case
seri
restrict
meaning
includ
recommend
part
made
era
cell
replet
haploident
transplant
area
intens
research
new
develop
might
impact
epidemiolog
outcom
viral
infect
hct
respiratori
viru
infect
continu
caus
diseas
pretranspl
well
posttranspl
period
taken
serious
especi
children
http
tend
shed
viru
longer
period
long
shed
time
implic
infect
control
therefor
personnel
patient
famili
properli
instruct
hand
hygien
case
pretranspl
infect
hct
defer
underli
diseas
condit
regimen
donor
avail
need
consid
pediatr
patient
also
tend
acquir
virus
frequent
favor
transplant
delay
elect
case
even
asymptomat
patient
without
doubt
diseas
progress
uri
lri
influenc
outcom
hct
recipi
number
risk
factor
share
respiratori
virus
associ
lri
occurr
lymphopenia
appear
specif
risk
factor
case
risk
factor
share
increas
mortal
steroid
use
time
lri
diagnosi
oxygen
requir
time
bal
sever
diseas
base
apach
ii
score
addit
myeloabl
condit
gvhd
bacteri
well
fungal
pulmonari
coinfect
especi
ifv
piv
infect
seem
worsen
outcom
possibl
reduc
risk
progress
uri
lri
might
chanc
coinfect
reduc
diagnos
treat
promptli
coinfect
could
easili
avoid
nosocomi
acquir
transfer
personnel
visitor
therefor
peopl
access
patient
awar
problem
also
shorten
lymphopen
interv
could
reduc
diseas
progress
might
achiev
stricter
withdraw
immunosuppress
drug
eg
steroid
milder
form
condit
earli
specif
diagnost
essenc
would
best
obtain
diagnost
sampl
straight
area
infect
ie
bal
materi
nasal
swab
case
lri
howev
might
sometim
impract
toler
patient
unless
specif
viral
agent
suspect
singl
duplex
pcr
order
eg
outbreak
novel
multiplex
assay
employ
also
identifi
bacteri
coinfect
novel
multiplex
assay
abl
quantifi
viral
load
clearli
potenti
help
identifi
patient
increas
risk
might
need
treatment
urgent
particularli
sinc
support
measur
like
radiolog
imag
techniqu
often
point
specif
pathogen
provid
nonspecif
result
regard
identif
pathogen
respons
howev
chest
xray
discov
inflammatori
process
delay
ct
find
might
help
differenti
pathogen
diagnost
step
carri
full
evalu
circumst
orderli
fashion
isi
rsi
tabl
might
help
identifi
patient
risk
await
valid
clinic
trial
eventu
antivir
avail
licens
treat
respiratori
viru
infect
sever
drug
test
hct
recipi
promis
result
publish
novel
antivir
compound
urgent
requir
might
use
combin
antivir
lymphocyt
current
develop
cmv
ebv
adv
bk
antiviru
ctl
us
european
intern
trial
trace
trial
product
cell
confin
special
laboratori
either
low
risk
score
moder
risk
score
high
risk
score
anc
absolut
neutrophil
count
alc
absolut
lymphocyt
count
gvhd
graftversushost
diseas
modifi
shah
et
al
calcul
rsi
score
predomin
pattern
lung
zone
multipli
extent
volumetr
radiolog
involv
eg
groundglass
opac
detect
six
lung
zone
volumetr
score
rsi
score
would
maximum
score
modifi
sheshadri
et
al
universitybas
commerci
howev
easili
access
expans
approach
target
respiratori
virus
might
similarli
use
halt
diseas
progress
uri
lri
final
applic
car
cell
combat
respiratori
viral
infect
might
option
futur
especi
combin
tumor
target
car
cell
howev
pulmonari
toxic
consid
due
crossreact
car
cell
nontarget
protein
also
ard
often
occur
sever
lri
might
worsen
cytokin
releas
syndrom
viral
pneumonia
still
remain
concern
hct
patient
new
drug
develop
along
sophist
cell
approach
diminish
complic
caus
respiratori
virus
cp
sv
wrote
edit
manuscript
work
support
intramur
fund
robert
koch
institut
